There is no sign of increased all-cause mortality following the use of paclitaxel-coated devices for the treatment of symptomatic peripheral arterial occlusive disease, a new study based on German claims data attests in the European Journal of Vascular and Endovascular Surgery.
Abbott has announced US Food and Drug Administration (FDA) approval of a new alternative surgical technique for Abbott’s HeartMate 3 heart pump that the company says will allow more advanced heart failure patients to avoid open heart surgery. The heart pump can now be implanted through an incision in the chest wall versus open heart surgery. The new, less invasive approach is designed to provide surgeons with a choice in surgical method for patients receiving the HeartMate 3 left ventricular assist device (LVAD), according to a statement from the company.
A retrospective registry comparing four self-expanding transcatheter heart valves has demonstrated good haemodynamic performance in small aortic annuli, with low post-procedure gradients, large orifice areas, and a low incidence of severe patient–prosthetic mismatch (PPM).
Proximo Medical has announced a partnership in select US markets with CeloNova Biosciences, supplier of the COBRA PzF nanocoated coronary stent (NCS).
Corindus has announced the completion of the first multicity, transcontinental percutaneous coronary intervention (PCI) simulations in the USA over three network connection types: 5G wireless, dedicated fibre, and commercial public internet networks. A press release reports that Ryan Madder (Frederik Meijer Heart & Vascular Institute, Grand Rapids, USA) successfully completed 36 cases in the same day between Waltham and New York City, and between Waltham and San Francisco (all USA).
Peripheral artery disease develops silently, narrowing blood vessels for decades until the supply of nutrients and oxygen falls low enough to cause cramps and leg pain.
Initially, the body may form smaller blood vessels around the blocked ones to reroute some blood.
Once the condition advances, those who experience it can develop severe leg cramps when they walk a lot, but that the pain disappears when they sit and the demand for nutrients and oxygen decreases.
Bluegrass Vascular Technologies has announced the publication of positive results associated with a clinical study involving the use of the Surfacer Inside-Out access catheter system in the peer-reviewed American Journal of Kidney Diseases.
Described as “deliberately challenging”, the new time-to-treatment targets published by the Vascular Society of Great Britain and Ireland (VSGBI), as part of the Peripheral Arterial Disease Quality Improvement Framework, have prompted a number of different measures in the UK for the treatment of patients with chronic limb-threatening ischaemia (CLTI).
A pivotal, multicentre clinical trial is exploring the use of an Impella heart pump (Abiomed) to unload the left ventricle for 30 minutes prior to coronary revascularisation. The aim of the trial is to test the hypothesis that unloading the left ventricle for 30 minutes prior to revascularisation reduces myocardial damage from a myocardial infarction and, as a result, leads to a reduced risk of a patient developing heart failure. The enrolment of the first patient in the STEMI DTU (ST-elevation myocardial infarction door-to-unloading) randomised trial enrolment took place at Spectrum Health (Grand Rapids, USA).
Laminate Medical Technologies (Laminate) has announced the completion enrolment of the VALUE study for the VasQ External Support. The postmarket study enrolled 80 patients (50 upper arm and 30 forearm fistulas) for sites across Germany, France, Spain, and the UK and will be followed for one year. The study is the first prospective study to assess the use of the device in the forearm. The forearm fistula carries a higher risk of primary failure relative to upper arm fistulas but is preferred by surgeons as it preserves more options for the patient’s future access needs.
George Dangas (Mount Sinai Hospital, New York, USA) told delegates in a late-breaking trial session at the American Heart Association Scientific Sessions (AHA 2019; 16–18 November, Philadelphia, USA) that “in patients without an established indication for oral anticoagulation after successful transcatheter aortic valve implantation (TAVI), a treatment strategy including rivaroxaban at a dose of 10mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy”.
A significant milestone has been reached for a landmark study into the use of short duration dual anti-platelet therapy (DAPT) in high-bleeding-risk (HBR) patients following stenting procedures, with patient recruitment just completed.
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389